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Bovine papillomaviruses (BPVs) are recognized as the causal agents of economical relevant diseases in cattle, associated with
the development of tumors in skin and mucosa. The oncogenesis process is mainly associated with different viral oncoprotein
expressions, which are involved in cell transformation. The expression and characterization of recombinant viral oncoproteins
represent an attractive strategy to obtain biotechnological products as antibodies and potential vaccines,Thus, the aim of this work
was to clone and express the BPV-1 and BPV-2 E6 recombinant proteins and perform in silico analysis in order to develop a strategy
for the systematic study of other papillomaviruses oncoproteins. The results demonstrated that BPV-1 and BPV-2 E6 recombinant
proteins were expressed and purified from bacterial system as well as its in silico analysis was performed in order to explore and
predict biological characteristics of these proteins.
1. Introduction
Different papillomaviruses (PVs) have been described as
infectious agents of the vertebrates species, including domes-
tic animals and human beings [1, 2]. The correlation between
the papillomavirus infection and the cellular malignant pro-
gression is associated with the expression of viral oncopro-
teins. These proteins act on different aspects of the tumoral
suppression cascades as well as on the ones that take part
in the control of cell cycle and immune response. Viral
oncoproteins can also interact with cellular DNA. Altogether,
these actions can induce mutational changes in the host cell
chromatin [3].
Currently, the Papillomaviridae family is divided into 16
genera according to their genomic organization [4, 5]. These
small (55–60 nm), nonenveloped viruses have a genome of
a double-stranded circular DNA molecule of approximately
eight kilobases [6], codifying functional, early (E) proteins,
and structural, late (L) proteins, expressed at different stages
of the viral cycle. With at least eight potential open read-
ing frames, the viral genome also consists of a noncoding
region, the long control region (LCR), associated with the
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viral transcriptional regulation. The E region encodes the
replication and transcription regulatory proteins E1, E2, and
the transforming proteins E5, E6, andE7,which are associated
with uncontrolled cell proliferation and differentiation [7].
The E4 protein formed by alternative splicing of genes E1
and E1/E4 transcripts (E1–E4) is associated with the release
of the virions through the disruption of the cytoskeleton
structure [8–10]. It is also shown that actin cytoskeleton was
altered in BPV-1 E6-transformed cells through E6 interaction
with the focal adhesion protein paxillin [11]. On the other
hand, the L region encodes structural proteins L1 and L2 that
assemble into the capsid during the viral particle maturation
[12]. Specifically, L1 is the most conserved gene within PV
genome and has therefore been used for the identification of
new PVs types [4].
The bovine papillomavirus (BPV) is recognized as the
causal agent of benign and malignant tumors in cattle, such
as cutaneous papillomas, urinary bladder, and esophagus
cancer. This virus is distributed worldwide, being associated
with severe economic losses in meat, milk, and leather
production. Thirteen types of the BPVs are currently well
characterized and classified into three distinct genera, Delta,
Epsilon, and Xi, and have been characterized and associated
with different histopathological lesions [13]. Specifically, the
BPV-1 and 2 are classified as Deltapapillomaviruses [14,
15]. Characteristically, these types induce the appearance
of fibropapillomas, associated with the recruitment of the
subepithelial fibroblasts [16] and have the ability to infect
different host species, not only bovines, causing the equine
sarcoid [15]. Lately, the genome of a new Delta-BPV type
(BPV-13) was fully sequenced [17].
The BPV-1 is commonly associated with lesions in the
teats and udder [13, 18, 19]. BPV-1 can cause fibropapillomas
of the penis, leading to necrosis and the loss of reproductive
function [20]. BPV-2 is the causal agent of malignant tumors
in the bladder [21]. Both types have also already been detected
in peripheral blood and in tissues of the reproductive tract,
and their vertical transmission has been suggested [16, 21–
26].
The first evidence of the oncogenic properties of E6
protein came from studies on human tumors cell lineages
derivate from uterine cervix where E6 was found expressed
and maintained many years after the initial transformation
events [27–29]. The E6 and E7 gene products are essential in
the process of cell transformation and immortalization [28,
30]. Particularly, E6 protein has a central role as a carcinogen
factor because it binds to p53, a major tumor suppressor
protein, inducing its degradation [4]. Studies conducted with
different cervical cancer cell lines infected with HPV-16
showed that the only expressed viral proteins were E6 and
E7, leading to the speculation that they could be expressed
like fusion proteins, an important indicator for the malignant
progression [31]. It is also suggested that the genes E6 and E7
have a synergic action during the induction of genital human
keratinocytes immortalization, although in some other cell
types, like mammary epithelial cells, they may act separately
[32].
Knowing the importance of E6 protein, the aim of this
work was to clone and express the BPV-1 and BPV-2 E6
recombinant proteins enabling the development of antibodies
and vaccines and to perform in silico analysis in order
to develop a strategy for the systematic study of other
papillomaviruses oncoproteins.
2. Material and Methods
2.1. E6-1 and E6-2 Gene Amplification. The following specific
primers were designed: E6-1 sense primer, 5󸀠-GAAAACCTG
TATTTTCAGGGCTAGGACCTGAAACCTTTTGC-3󸀠; and
E6-1 antisense primer, 5󸀠-GGCCTCGAGCTGCAGGTGAAT
CATCCAAG-3󸀠, E6-2 sense primer, 5󸀠-GAAAACCTGTAT
TTTCAGGGCATGGACCTGCAAAGTTTTTC-3󸀠; and E6-
2 antisense primer, 5󸀠-GGCCTCGAGGAATCATCCAAG
TTTCTA-3󸀠. Underlined letters indicate the nucleotides for
TEV protease site, and italic underlined letters indicate XhoI
restriction site.The primers were designed based on complete
genome sequences deposited in GenBank (accession num-
bers X02346 and M20219.1). These primers were used in a
PCR reaction to amplify E6 gene, using the genomic DNA
of BPV-1 or BPV-2 previously cloned in pAT153 vector as
a template [33]. A Palm- Corbett Cycler Cobbert Research
Version 2.1.7 (Uniscience) was used with the following
amplification program: an initial denaturation step at 95∘C for
4min followed by 30 cycles at 95∘C for 1min, 50∘C for 30 sec,
72∘C for 1min, and finally, 5min elongation step at 72∘C.
2.2. Cloning and Subcloning. The amplified PCR products
were detected in a 1% agarose gel electrophoresis, excised
from the gel, and purified with Invisorb Fragment Clean
Up Kit (Invitek). The purified amplicons were cloned in
pCR4-TOPO vector (Invitrogen). The resulting constructs
were cloned in transformed E. coli DH5a competent cells,
and positive clones were selected from plates supplemented
with ampicillin. Plasmid DNA was prepared from overnight
grown cultures with a WIZARD Mini Prep Purification Kit
(Promega) following the manufacturer’s recommendations.
Plasmids were digested with EcoRI and XhoI to check the
insert presence. Purified inserts were subcloned into the pET-
28(+) vector (Merck), which was previously digested with the
same enzymes. T4 DNA ligase (Invitrogen) was used for the
ligation reaction. Recombinants pET-E61 and pET-E62 were
then used to transform E. coli BL21 (DE3) competent cells
cells by heat shock. Positive recombinant clones were selected
on LB plates containing kanamycin, and the correct insertion
of the E6 ORF into the cloning sites was verified by DNA
sequencing.
2.3. Protein Expression. Transformed E. coli BL21 (DE) cells
harboring the correct expression construct (pET-E61 and
pET-E62) were grown in 1L LB broth containing kanamycin
(50𝜇g/mL) at 37∘C until the growth reached log phase
(OD600 = 0.6). IPTG at a final concentration of 1mM
was added to the cultures to induce recombinant protein
expression. Induced bacterial cultures were pelleted by cen-
trifugation at 10,000 g for 30min at 4∘C.
BioMed Research International 3
(a) (b)
(c) (d)
Figure 1: Electron microscopy E. coli BL21 (DE) not induced and induced by IPTG. (a) Transformed bacteria—plasmid pET-28a, without
E6-1 not induced, 12.930X; (b) transformed bacteria—plasmid pET-28a, without E6-1 induced, 16.700X; (c) transformed bacteria—plasmid
pET-28a, with E6-1 not induced, 35.970X; (d) transformed bacteria—plasmid pET-28a, with E6-1 induced 27.800X. Arrows: inclusion bodies.
Transmission Microscopy LEO 906E, Laborato´rio de Biologia Celular do Instituto Butantan.
M NID ID NIE IE
15kDa
(a)
M NID ID NIE IE
15kDa
(b)
Figure 2: (a) Induction of E6-1 recombinant protein. M: molecular weight marker; NID: noninduced D colony; ID: induced D colony; NIE:
noninduced E colony; IE: induced E colony. SDS-PAGE 17% stained with Coomassie blue. (b)Western blotting of E6-1 recombinant protein
induction. M: molecular weight marker; NID: noninduced D colony; ID: induced D colony; NIE: noninduced E colony; IE: induced E colony.
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Figure 3: Topology diagram recombinants E6-1 and E6-2, respective sequences (a) E6-1 recombinant; (b) E6-2 recombinant.
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Figure 4: Antigenicity-recombinants E6-1 and E6-2, (a) E6-1 recombinant; (b) E6-2 recombinant.
2.4. ElectronMicroscopy. Samples of transformed E. coli BL21
cultured cells with the recombinant plasmid E6-1/pET-28a
and with the empty pET-28a vector (negative control) were
induced for recombinant protein expression. Fractions of
these cultures were centrifuged and resuspended in approxi-
mately 1.0mL of glutaraldehyde. These samples were sent to
theDepartment of Cell Biology andDevelopment at the Insti-
tute of Biomedical Sciences-ICB II to be prepared for electron
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The conservation scale:
1 2 3 4 5 6 7 8 9
Variable Average Conserved
An exposed residue according to the neural-network algorithm.
A buried residue according to the neural-network algorithm.
A predicted functional residue (highly conserved and exposed).
A predicted structural residue (highly conserved and buried).
Insufficient data–the calculation for this site was
performed on less than 10% of the sequences.
e:
b:
f: 
s:
X: 
(b)
Figure 5: Protein sequences E6-1 e E6-2 conservation levels. (a) E6-1 recombinant; (b) E6-2 recombinant. CXXC red.
microscopy (ME) for the verification of the E6 recombinant
expression through the observation of inclusion bodies. ME
observations and image recording were performed at the
Laboratory of Cellular Biology, Instituto Butantan, using a
transmission electron microscope LEO 906E.2.5.
2.5. Protein Purification. In order to purify the E6 recom-
binant proteins, the bacterial pellets were resuspended in
20mMTrisHCl, NaCl 500mM, and pH 8.0, supplemented
with protease inhibitor (PMSF at a final concentration of
2mM), and lysed with a French Press. The cell lysates were
centrifuged at 6000 g for 60min at 4∘C. The pellets were
resuspended in 20mMTrisHCl, 500mMNaCl, 8Mureia,
50mM imidazole, pH 8.0, and final volume 25mL. Aliquots
of the clarified suspension were collected and analyzed in
17% SDS-PAGE. These tagged recombinant proteins were
purified by Ni Sepharose 6 Fast Flow (GE Health Care):
the clarified supernatants were passed through columns of
charged resin and subsequently washed with 20mM Tris-
HCl, pH 8.0, 500mMNaCl, 6M urea, and 50mM imidazole.
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The recombinant proteins were then eluted with 500mM
imidazole in the same buffer. The proteins quantification
was determined by the Bradford method [34]. Purified
recombinant proteins were separated by 17% SDS-PAGE
and transferred to nitrocellulose membranes. Membranes
were blocked with 5% powdered nonfat dry milk in phos-
phate buffered saline containing 0.05% Tween 20 (PBST)
and incubated for 2 h using anti-his monoclonal antibody
(GE) (1 : 3000). Blots were then submitted to three 5min
washes with TBST and incubated with Goat Anti-Mouse IgG
Horseradish Peroxidase (1 : 2000) for 1 h at room temperature.
Bands were visualized by chemiluminescence reaction in the
presence of H
2
O
2
and using diaminobenzidine (DAB). The
reaction was stopped with distilled water.
2.6. Bioinformatics. The nucleotide sequences generated by
sequencing of E6-1 and E6-2 cloned genes were translated
into amino acids with the BioEdit 7.1.3.0 [35]. The obtained
nucleotide and amino acids sequences were aligned with
sequences deposited in Nucleotide Collection and Protein
Data Bank using BLASTN and BLASTP algorithms (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Sequence alignments were
also performed using the BioEdit software, and the identity
matrixwas calculated.The topology diagrams of the recombi-
nant proteins was generated with the PDBsum software [36].
The analysis of conserved regions of the proteins E6-
1 to E6-2 recombinants were performed by comparing all
E6 protein sequences of other PVs already deposited using
ConSurf server [37]. The degree of conservation for each
amino acid was pointed out in a linear sequence.
In addition, the analysis of the antigenicity properties was
performed using the JaMBW Edition 1.1 software [38].
3. Results and Discussion
3.1. E6-1 and E6-2 Gene Amplification and Cloning. E6-1
and E6-2 gene PCR products showed bands in the gel with
approximately 500pb. E6-1/TOPO and E6-2/TOPOwere suc-
cessfully cloned in E. coli DH5a competent cells as indicated
with double digestion of the recombinant TOPO vectors.
Subsequently, E6-1/pET and E6-2/pET were subcloned in E.
coli BL21 competent cells as indicated by double digestion
and sequencing. DNA sequencing showed that the cloned
genes were inserted in the correct frame of pET-28a (+). The
primers sets were also effective for DNA sequencing.
3.2. Electron Microscopy. In regard to electronic microscopy
(EM), both induced and noninduced cultured bacteria used
as negative control (transformed with pET-28a, but without
E6 insert) showed no inclusion corpuscles (Figures 1(a) and
1(b)). On the other hand, EM of the cultured, induced E.
coli BL21 cells transformed with E6-1/pET-28a revealed the
presence of inclusion bodies (Figure 1(d)), suggesting the
presence of recombinant protein expression. As before, these
were not observed in noninduced E6-1/pET-28a bacteria
(Figure 1(c)). Papillomavirus E6 proteins are notoriously
difficult to express and purify and unfused E6 proteins
form insoluble aggregates upon bacterial overexpression [39].
Table 1: Mutations in nucleotide and aminoacid sequences of BPV1
E6 (bold).
E6 BPV-1
Nucleotide Codon Amino acid
Position Ref. Rec. Ref. Rec. Ref. Rec. Position
48 T → C GAU → GAC D = D 16
73 A → T ACA → UCA T ̸= S 25
78 A → G GAA → GAG C = C 26
155 T → C AUU → ACU I ̸= T 52
Ref.: reference sequences (accession number X02346 and PDB codes 3PY7);
Rec.: recombinant sequences obtained in this study.
However, in this study, the feasibility of E6-1 and E6-2 purifi-
cations from a bacterial expression systemwas demonstrated.
3.3. E6 Recombinant Protein Expression and Purification.
Cloning and expression of different papillomavirus oncopro-
teins in bacterial vectors have already been done, enabling
structural studies [40]. In the present work, the E6 gene of
both BPV-1 and BPV-2 was cloned in a bacterial expression
system, with the respective recombinant proteins being puri-
fied.
SDS-PAGE and Western blotting analysis using an anti-
his tag antibody demonstrated that the large majority of
detected fusion proteins migrated predominantly as a single
bandwith an approximate expectedmolecularmass of 16 kDa
(Figure 2(a)). However,Western blotting showed other bands
also, indicating the possible occurrence of protein dimeriza-
tion (Figure 2(b)). The purified recombinant eluted proteins
were also examined by SDS-PAGE and Western blotting as
before, with observed bands being approximately 16 kDa.
3.4. Bioinformatics Analysis
3.4.1. Alignment and Identity Matrix. The identity matrix
showed 0.99 of similarity between E6-1 recombinant and
reference (X02346) sequences of nucleotides.The amino acid
sequence of the E6-1 recombinant protein showed 0.99 of
identity with PDB codes 3PY7 sequence which has been
considered as the protein sequence reference.
It was observed that, when translated into amino acids,
two mutations (A78G and T48C) were silent, that is, no
change in the amino acids was generated. The other two
mutations (A73T and T155C) generated different amino acids
(Table 1).
Differences between recombinant cloned E6-2 and
deposited corresponding sequences were also observed.
The identity matrix showed 0.99 of similarity between
E6-2 recombinant and reference (M20219.1) sequences of
nucleotides. Amino acid sequence of the E6-2 recombinant
protein showed 0.98 of identity with UniProtKB/Swiss-Prot
codes P11302.1 sequence which has been considered as the
protein sequence reference. It was observed that, when
translated into amino acids, all three mutations (T68C,
T45G, and A405C) generated different amino acids (Table 2).
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Table 2:Mutations in nucleotide and aminoacid sequences of BPV2
E6 (bold).
E6 BPV-2
Nucleotide Codon Amino acid
Position Ref. Rec. Ref. Rec. Ref. Rec. Position
68 C → T CCU → CUU P ̸= L 23
134 G → T GUG → UUG V ̸= L 45
405 C → A AAC → AAA N ̸= K 135
Ref.: reference sequences (accession number M20219.1 and UniProtKB/
Swiss-Prot codes P11302.1); Rec.: recombinant sequences obtained in this
study.
3.4.2. Topology. Topology diagram of recombinant proteins,
E6-1 and E6-1 was generated. The presence of seven 𝛽-
sheets and five 𝛼-helices was observed in both diagrams
(Figures 3(a) and 3(b)).
3.4.3. Antigenicity Prediction. According to the antigenicity
graph, E6-1 recombinant protein sequence showed one peak
near amino acids 90 and 100 (CCYCGGKLTKNEKHR), and
E6-2 recombinant protein showed two peaks near amino
acids 50 and 60 (CTTCLENCLDKE), and amino acids 90 and
100 (CCYCGGKLTKNEKQR) were predicted as especially
immunogenic (Figures 4(a) and 4(b)). Interestingly, these
potential immunogenic, mapped regions could represent
targets for the development of new designed antibodies.
3.4.4. Conserved Regions. In silico prediction identified con-
served regions between E6-1 to E6-2 proteins as well as
from other papillomaviruses species. CXXC motifs were
localized at regions associated with the binding of zinc atoms
(Figures 5(a) and 5(b)).
Usually, papillomavirus E6 proteins share a common
architecture consisting of two zinc-binding domains (E6-N
and E6-C). These structural features indicated that E6 can
interact directly with DNA molecule, acting as a transcrip-
tional activator [41–43]. Both BPV-1 and BPV-2 encode an
E6 protein of 137 amino acids that acts as a transcriptional
activator, p53 and paxillin ligand, presenting also telomerase
activity. Here, the primary amino acid sequences of these
recombinant proteins were analyzed in silico for comparison
with virtual protein sequences deposited in GenBank. The
presence of divergences which may represent functional
differences were observed. It is emphasized that the DNA
sequencing in our laboratory was redundant in order to cover
the entire E6 gene sequence for at least three times.
Among papillomaviruses oncoproteins, conserved re-
gionsweremaintained in regard to the structure and function
of these proteins. For example, E7 protein has 127 amino acids
and a zinc finger domain [44]. Recombinant E7 protein with
mutated regions showed lower efficiency in transforming
activity [45]. On the other hand, several studies indicated that
the hydrophobic nature of the BPV E5 protein has a crucial
importance in conferring the transforming activity [46].
These essential amino acid residues are highly conserved
among papillomaviruses as previously reported [47].
4. Conclusions
The cloning and recombinant protein expression of E6-1 and
E6-2 in bacterial system proved to be a feasible methodologi-
cal approach. For the first time, BPV-2 E6 protein is expressed
and purified in a bacterial system.The purification of E6 BPV
recombinant protein as well its structural and antigenicity
analyses could allow the production of biotechnology mate-
rial such as antibodies and vaccines candidates. This work
could be also employed as amodel for the obtainment of other
papillomaviruses recombinant oncoproteins.
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